Financial Performance - The company expects a net profit of approximately 156.4 million yuan for 2024, a decrease of about 665.7 million yuan, representing a year-on-year decline of approximately 80.98%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be around 134.21 million yuan, down about 640.2 million yuan, with a year-on-year decline of approximately 82.67%[2] - The total profit reported for 2023 was 1,026.6 million yuan, with a net profit attributable to shareholders of 822.1 million yuan[5] Revenue Expectations - The company anticipates a revenue decrease of approximately 3.213 billion yuan in 2024, reflecting a decline of 20.56%, with Q4 revenue expected to drop by about 1.464 billion yuan, a decline of 42.5%[6] R&D and Innovation - The company maintains a strong commitment to R&D investment, focusing on new product development and enhancing existing product lines through technological innovation[6] Operational Strategies - The company is actively optimizing its marketing model and strengthening operational control to improve sales performance[6] Non-recurring Items - Non-recurring gains and losses for 2024 are estimated to be around 22.19 million yuan, including government subsidies and asset disposal gains[6] Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[7] - The data provided is preliminary and subject to change pending the audited annual report for 2024[8]

Revenue and Profit Performance - Revenue for the third quarter of 2024 was RMB 2,616,652,515.62, a decrease of 16.44% compared to the same period last year[2] - Net profit attributable to shareholders of the company for the third quarter of 2024 was RMB 50,462,191.25, a decrease of 73.82% compared to the same period last year[3] - Net profit attributable to shareholders of the company after deducting non-recurring gains and losses for the third quarter of 2024 was RMB 30,638,822.80, a decrease of 78.63% compared to the same period last year[3] - Basic earnings per share for the third quarter of 2024 was RMB 0.09, a decrease of 74.29% compared to the same period last year[3] - The company's total revenue for the first three quarters of 2024 was RMB 10,433,818,061.19, a decrease of 14.36% compared to the same period last year[2] - Total operating income for the first three quarters of 2024 was RMB 10,433,818,061.19, a decrease from RMB 12,182,741,633.45 in the same period in 2023[16] - Operating profit for the third quarter of 2024 was RMB 662.97 million, compared to RMB 913.67 million in the same period last year[18] - Net profit attributable to shareholders of the parent company was RMB 545.07 million, down from RMB 758.10 million year-on-year[18] - Basic earnings per share (EPS) for the third quarter of 2024 was RMB 0.98, compared to RMB 1.36 in the same period last year[19] - Revenue from sales of goods and services was RMB 8.95 billion, down from RMB 10.97 billion year-on-year[20] Assets and Liabilities - Total assets as of the end of the third quarter of 2024 were RMB 14,334,261,372.81, a decrease of 0.54% compared to the end of the previous year[3] - Equity attributable to shareholders of the company as of the end of the third quarter of 2024 was RMB 4,000,995,355.63, an increase of 10.46% compared to the end of the previous year[3] - Total current assets as of September 30, 2024, amounted to RMB 7,266,196,048.02, a decrease from RMB 7,604,664,368.90 at the end of 2023[13] - Monetary funds decreased significantly to RMB 689,877,893.51 from RMB 1,935,008,857.17 at the end of 2023[13] - Accounts receivable increased to RMB 2,756,640,228.88 from RMB 1,978,057,763.16 at the end of 2023[13] - Inventory increased to RMB 2,969,338,906.41 from RMB 2,690,632,474.71 at the end of 2023[13] - Total assets as of Q3 2024 were RMB 14,334,261,372.81, slightly lower than RMB 14,411,774,083.52 at the end of 2023[14] - Fixed assets decreased to RMB 3,823,116,212.51 in Q3 2024 from RMB 3,935,631,862.17 at the end of 2023[14] - Total liabilities as of Q3 2024 were RMB 10,207,713,647.74, down from RMB 10,665,932,484.04 at the end of 2023[15] - Short-term borrowings increased to RMB 4,015,787,143.20 in Q3 2024 from RMB 3,284,091,451.45 at the end of 2023[14] - Net profit attributable to the parent company's owners was RMB 1,264,909,717.99 in Q3 2024, up from RMB 886,902,222.20 at the end of 2023[15] - Investment in construction projects increased significantly to RMB 1,102,629,001.63 in Q3 2024 from RMB 731,099,260.38 at the end of 2023[14] Cash Flow - The company's net cash flow from operating activities for the first three quarters of 2024 was negative RMB 690,343,647.89[3] - Cash flow from operating activities was negative RMB 690.34 million, compared to negative RMB 476.43 million in the same period last year[21] - Cash flow from investing activities was negative RMB 605.58 million, compared to negative RMB 374.84 million in the same period last year[21] - Cash flow from financing activities was positive RMB 208.16 million, compared to negative RMB 356.36 million in the same period last year[21] - Total cash and cash equivalents at the end of the third quarter of 2024 were RMB 565.11 million, down from RMB 764.39 million at the end of the same period last year[22] - Total cash inflows from operating activities were RMB 9.43 billion, down from RMB 11.56 billion year-on-year[20] - Total cash outflows from operating activities were RMB 10.12 billion, down from RMB 12.04 billion year-on-year[20] Shareholder Information - The top shareholder, Taiji Group Co., Ltd., holds 153,812,354 shares of common stock[8] - Hong Kong Securities Clearing Company Limited holds 10,928,280 shares of common stock[8] - China Industrial and Commercial Bank Co., Ltd. - Hua'an Media Internet Hybrid Securities Investment Fund holds 7,993,100 shares of common stock[8] - China Agricultural Bank Co., Ltd. - CSI 500 ETF holds 6,388,008 shares of common stock[8] - China Construction Bank Co., Ltd. - Hua'an Shanghai-Hong Kong-Shenzhen Flexible Allocation Hybrid Securities Investment Fund holds 5,463,500 shares of common stock[8] - The top 10 shareholders and top 10 unrestricted shareholders did not participate in margin trading or securities lending[9] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 9,822,423,663.75, down from RMB 11,311,905,251.05 in 2023[16] - R&D expenses increased to RMB 187,490,437.20 in the first three quarters of 2024, compared to RMB 148,932,719.38 in the same period in 2023[16] - Sales expenses decreased to RMB 2,882,949,492.55 in the first three quarters of 2024 from RMB 4,162,454,161.64 in the same period in 2023[16] Government Subsidies and Return on Equity - Government subsidies received during the reporting period amounted to RMB 9,116,598.86[4] - The company's weighted average return on equity for the third quarter of 2024 was 1.32%, a decrease of 3.87 percentage points compared to the same period last year[3]

证券代码：600129 证券简称：太极集团 公告编号：2024-055 重庆太极实业（集团）股份有限公司 关于召开 2024 年第三季度业绩说明会的公 告 重庆太极实业（集团）股份有限公司（以下简称"公司"）已于 2024 年 10 月 25 日发布公司 2024 年第三季度报告，为便于广大投资 者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公 司计划于 2024 年 11 月 19 日下午 14:00-15:00 举行 2024 年第三季度 业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 19 日(星期二)下午 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 ...

证券代码：600129 证券简称：太极集团 公告编号：2024-050 重庆太极实业（集团）股份有限公司 关于注射用青霉素钠通过仿制药一致性评价 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司）控股 子公司西南药业股份有限公司（以下简称：西南药业）收到国家药品监督 管理局关于注射用青霉素钠（规格：0.48g、0.96g、2.4g）的《药品补充 申请批准通知书》，西南药业注射用青霉素钠通过仿制药质量和疗效一致 性评价。现将相关情况公告如下： 二、药品其他相关信息 青霉素适用于敏感细菌所致的各种感染，如脓肿、菌血症、肺炎和心 内膜炎等。其中青霉素为以下感染的首选药物： 1．溶血性链球菌感染，如咽炎、扁桃体炎、猩红热、丹毒、蜂窝织炎 和产褥热等。 2．肺炎链球菌感染如肺炎、中耳炎、脑膜炎和菌血症等。 3．不产青霉素酶葡萄球菌感染。 4．炭疽 5．破伤风、气性坏疽等梭状芽孢杆菌感染。 5．梅毒（包括先天性梅毒）。 1 药品名称 注射用青霉素钠 剂 型 注射剂 申请事项 ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥7.82 billion, a decrease of 13.64% compared to the same period last year[16]. - The net profit attributable to shareholders for the first half of 2024 was approximately ¥494.61 million, down 12.51% year-on-year[16]. - The basic earnings per share for the first half of 2024 were ¥0.89, a decrease of 12.75% compared to the same period last year[17]. - The weighted average return on net assets for the first half of 2024 was 12.78%, down 4.16 percentage points from the previous year[17]. - The company achieved operating revenue of 7.817 billion yuan in 2024, a year-on-year decrease of 13.64%[26]. - The pharmaceutical industry segment generated sales revenue of 5.079 billion yuan, down 19.77% year-on-year, while the health segment saw a revenue increase of 79.63% to 265 million yuan[26]. - Net profit attributable to shareholders was 495 million yuan, reflecting a year-on-year decline of 12.51%[27]. - The company reported a significant reduction in financial expenses by 2.47% to ¥59,372,266.69, attributed to lower loan interest rates[37]. - The company reported a total comprehensive income for the first half of 2024 amounted to ¥570,788,518.25, with a significant contribution from the net profit of ¥565,332,876.60[123]. Cash Flow and Liquidity - The net cash flow from operating activities for the first half of 2024 was approximately -¥357.24 million, indicating a negative cash flow situation[16]. - The net cash flow from operating activities improved, with a reduction in negative cash flow from ¥428,546,424.50 to ¥357,244,328.97[37]. - The company's cash and cash equivalents decreased by 51.51% to ¥938,228,016.40, primarily due to an increase in accounts receivable[38]. - The company reported a significant increase in cash received from other operating activities, amounting to 3,806,423,021.99 RMB, compared to 1,527,525,369.53 RMB in the previous year, representing a growth of about 149.5%[116]. - The ending balance of cash and cash equivalents was 713,484,147.68 RMB, down from 410,824,758.59 RMB in the previous year, reflecting a decrease of about 73.1%[118]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥14.75 billion, an increase of 2.34% compared to the end of the previous year[16]. - The total liabilities decreased significantly, with accounts payable down by 72.34% to ¥176,628,505.69, reflecting improved cash management[38]. - The company's total liabilities amounted to ¥10,672,005,917.29, slightly up from ¥10,665,932,484.04, showing a marginal increase of 0.01%[101]. - The company's equity attributable to shareholders rose to ¥3,950,677,184.70 from ¥3,622,185,106.00, an increase of approximately 9.07%[101]. - The total equity of the company at the end of the reporting period is RMB 3,521,973,871.97, a decrease of RMB 109,288,127.45 compared to the previous period[125]. Research and Development - The company has 56 ongoing research projects, focusing on innovative drugs and traditional Chinese medicine, with significant progress in key projects[27]. - Research and development expenses increased by 31.30% to ¥116,344,634.48, reflecting a commitment to enhance R&D investment[37]. - The company is committed to developing innovative drugs targeting 12 major diseases, leveraging modern technology and digital methods[21]. - The company has developed over 40 new drugs and received more than 30 national new drug certificates, showcasing its strong R&D capabilities[25]. - The company emphasizes quality control in its raw material sourcing, implementing a "traceable planting" approach for over 50 types of medicinal materials[25]. Market and Competitive Environment - The pharmaceutical industry is experiencing increasing demand due to aging population and rising health awareness, presenting new opportunities for growth[23]. - The government is enhancing regulations on drug pricing and quality, promoting a more transparent and standardized market[23]. - The company is facing market and policy risks due to increasing competition and regulatory changes in the pharmaceutical industry, which may impact revenue and profit[50]. - The company aims to strengthen its core competitiveness through R&D investment and innovation capabilities[23]. - The company is committed to improving its market competitiveness by enhancing brand-driven strategies and exploring new profit growth points[50]. Environmental Responsibility - The company has three subsidiaries listed as key pollutant discharge units by environmental protection authorities, indicating a focus on environmental responsibility[52]. - The carbon emissions from Fuling Pharmaceutical Factory for the first half of the year amounted to 46,011 tCO2e, with the quota yet to be assigned[53]. - The company has implemented a comprehensive environmental management system, achieving certifications for both environmental and energy management[65]. - The company reduced carbon emissions by 1,136 tons during the reporting period through various measures, including the adoption of distributed photovoltaic power generation and energy efficiency improvements[66]. - The company has established emergency response plans for environmental incidents, with all relevant documentation filed with authorities[60]. Corporate Governance and Shareholder Information - The company will not distribute profits or increase capital reserves in the first half of 2024, with no dividends or stock bonuses planned[51]. - The largest shareholder, Taiji Group Co., Ltd., holds 153,812,354 shares, representing 27.62% of the total shares[94]. - The report indicates a decrease of 5,965,734 shares held by the Industrial and Commercial Bank of China - Central European Medical Health Mixed Securities Investment Fund[94]. - The report does not indicate any new strategic investors or changes in the controlling shareholder[97]. - The company has not reported any changes in the board of directors or senior management during the reporting period[97]. Accounting Policies and Financial Reporting - The financial statements are prepared based on the assumption of going concern, with no significant doubts regarding the company's ability to continue operations for the next 12 months[128]. - The company adheres to the accounting standards for enterprises, ensuring that the financial statements accurately reflect its financial position and operating results[130]. - The company applies a weighted average method for inventory valuation in retail and industrial sectors[153]. - The company recognizes revenue based on the performance obligations identified in contracts, confirming revenue at the point when control of goods or services is transferred to the customer[179]. - The company assesses the recoverability of deferred tax assets based on the likelihood of generating sufficient taxable income in future periods[182].

证券代码：600129 证券简称：太极集团 公告编号：2024-044 重庆太极实业（集团）股份有限公司 关于召开 2024 年半年度业绩说明会的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 会议召开时间：2024 年 9 月 12 日(星期四)上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） （一）会议召开时间：2024 年 9 月 12 日上午 09:00-10:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 9 月 5 日(星期四)至 9 月 11 日(星期三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱 tjzq@taiji.com 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 重庆太极实业（集团）股份有限公司（以 ...

证券代码：600129 证券简称：太极集团 公告编号：2024-043 重庆太极实业（集团）股份有限公司 关于子公司桐君阁药厂拟建设 新厂区一期工程的公告 项目建设单位：太极集团重庆桐君阁药厂有限公司（以下简称：桐 君阁药厂）。 项目投入金额：128,435.48 万元。 特别风险提示：本次拟建设项目符合公司的发展战略规划布局，公 司做了充分的调研和分析，但仍然存在政策、市场、建设过程中质量、 安全、进度等不确定性风险。 一、项目建设概述 （一）重庆太极实业（集团）股份有限公司（以下简称：公司） 间接控股子公司桐君阁药厂是公司四大产能中心之一。为解决桐君阁 药厂"一厂五地"、产能不足等问题，桐君阁药厂拟投资 128,435.48 万元，在重庆经开区东港片区新征地 164.71 亩，新建桐君阁中药智 能制造暨中药文化展示传承项目一期工程项目。 （二）2024 年 8 月 21 日，公司第十届董事会第二十次会议审议 通过了《关于新建桐君阁药厂中药智能制造暨中药文化展示传承项目 一期工程的议案》，本次投资属于公司董事会审议范围，无需提交公 司股东大会审议。 重要内容提示： （三）本建设项目不属于关联交易，亦不构成《 ...

法定代表人：杨珊华 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 重庆太极实业（集团）股份有限公司 关于对国药集团财务有限公司的风险持续 评估报告 按照《上海证券交易所上市公司自律监管指引第5号——交易与 关联交易》的要求，重庆太极实业（集团）股份有限公司（以下简称: 公司）通过查验国药集团财务有限公司（以下简称：国药财务公司） 《金融许可证》《企业法人营业执照》等证件资料，并审阅了国药财 务公司截至2024年上半年的财务报告以及风险指标等必要信息，对国 药财务公司的经营资质、业务和风险状况进行了评估，具体情况报告 如下： 一、国药财务公司基本情况 国药财务公司成立于2012年2月，是经原中国银行业监督管理委 员会批准成立的非银行金融机构。 企业名称：国药集团财务有限公司 注册地址：北京市海淀区知春路20号 目前国药财务公司注册资本金为人民币220,000万元，股权结构 如下表所示： | 序号 | 股东名称 | 出资额（万元） | 持股比例 | | --- | --- | --- | --- | | 1 | 中国医药集团有限公司 | 116,105 ...

重庆太极实业（集团）股份有限公司 关于公司 2024 年半年度募集资金存放 与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第2号-上市公 司募集资金管理和使用的监管要求》《上海证券交易所上市公司自律 监管指引第1号-规范运作》等相关法规及公司《募集资金管理办法》 的规定，公司拟定了《2024年半年度募集资金存放与实际使用情况的 专项报告》。该专项报告已经公司第十届董事会第二十二次会议和第 十届监事会第十八次会议审议通过。公司2024年半年度募集资金存放 与使用情况如下： 一、募集资金基本情况 证券代码：600129 证券简称：太极集团 公告编号：2024-042 经中国证券监督管理委员会《关于核准重庆太极实业（集团）股 份有限公司非公开发行股票的批复》（证监许可【2017】1366 号） 核准，公司向太极集团有限公司等 8 名特定对象发行股票，本次非公 开发行股票 129,996,744 股，发行价格为 15.36 元/股，募集资金总 额为 1,996, ...

证券代码：600129 证券简称：太极集团 重庆太极实业（集团）股份有限公司 简式权益变动报告书 上市公司名称：重庆太极实业（集团）股份有限公司 信息坡露义务人：重庆市涪陵页岩气产业投资发展有限公司 住所：重庆市涪陵区中山路9号（金科世界走廊）A区26-5（自主承诺） 权益变动性质：增加（国有股无偿划转） 签署时间：2024 年 7 月 31 日 1 上市地点：上海证券交易所 股票简称：太极集团 股票代码： 600129 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称：《证券法》）、 《上市公司收购管理办法》（以下简称：《收购办法》）、《公开发行证券公司 信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称：《15 号准则》） 等相关法律、法规、规范性文件编写本权益变动报告书。 二、信息披露义务人签署本权益变动报告书已获得必要的授权和批准，其履 行亦不违反信息披露义务人章程及内部规定中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《15 号准则》等法律法规的规定，本报告 书已全面披露了信息披露义务人在重庆太极实业（集团）股份有限公司（以下简 称：太极集团）拥 ...